Difference between revisions of "LoConte NK, et al. Invest. N. Drugs (2015) cited as Ref 590 in DOI: 10.1038/s41392-020-0110-5 (Q9853)"
Jump to navigation
Jump to search
(Created claim: DOI Identifier (P138): 10.1007/s10637-014-0166-6, #quickstatements; #temporary_batch_1590000649558) |
(Created claim: Publication Date (P100): 2015, #quickstatements; #temporary_batch_1590002823654) |
||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2015
| ||||||||||||||
| Property / Publication Date: 2015 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Revision as of 19:48, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
LoConte NK, et al. Invest. N. Drugs (2015) cited as Ref 590 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
LoConte NK
0 references
2015
0 references
